Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Working Capital Changes (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Working Capital Changes for 15 consecutive years, with $4818.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 102.58% to $4818.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4818.0, a 100.09% increase, with the full-year FY2025 number at $451000.0, up 14387.63% from a year prior.
  • Other Working Capital Changes was $4818.0 for Q4 2025 at Aytu Biopharma, up from -$403000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.5 million in Q1 2023 to a low of -$4.4 million in Q2 2023.
  • A 5-year average of -$363048.7 and a median of -$16450.0 in 2022 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 1653.17% in 2021, then tumbled 30506.5% in 2024.
  • Aytu Biopharma's Other Working Capital Changes stood at $2.0 million in 2021, then tumbled by 99.99% to $100.0 in 2022, then skyrocketed by 515.0% to $615.0 in 2023, then crashed by 30506.5% to -$187000.0 in 2024, then surged by 102.58% to $4818.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Working Capital Changes are $4818.0 (Q4 2025), -$403000.0 (Q3 2025), and $2889.0 (Q1 2025).